BC
RARE icon

BIT Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

BIT Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Buy
91,391
+73,391
+408% +$1.82M 0.09% 56
2026
Q1 		$377K Buy
+18,000
New +$405K 0.02% 77
2025
Q3 		– Sell
-2,055
Closed -$74.7K – 120
2025
Q2 		$74.7K Sell
2,055
-19,600
-91% -$707K ﹤0.01% 78
2025
Q1 		$784K Sell
21,655
-8,215
-28% -$342K 0.07% 64
2024
Q4 		$1.26M Hold
29,870
– – 0.1% 65
2024
Q3 		$1.66M Sell
29,870
-2,385
-7% -$121K 0.15% 54
2024
Q2 		$1.33M Sell
32,255
-8,745
-21% -$373K 0.1% 64
2024
Q1 		$1.91M Buy
41,000
+39,445
+2,537% +$1.86M 0.14% 67
2023
Q4 		$74.4K Buy
+1,555
New +$60.3K 0.01% 94

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BIT Capital's RARE Position: Q2 2026 in Review

BIT Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 408% in Q2 2026, buying an estimated $1.82M and bringing the position to 91,391 shares worth $3.05M. The position accounts for 0.09% of the portfolio, ranked #56.

BIT Capital first reported a position in RARE in Q4 2023 and has held it in 9 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • BIT Capital held 91,391 shares of Ultragenyx Pharmaceutical worth $3.05M as of Q2 2026.
  • BIT Capital bought 73,391 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.82M.
  • Ultragenyx Pharmaceutical made up 0.09% of BIT Capital's portfolio in Q2 2026, its #56 holding.
  • BIT Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 9 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on BIT Capital's 13F filing for Q2 2026, filed 12 Aug 2026.